Protein may trigger treatment-resistant prostate cancer; Galectin-3 backed as cancer marker;

> Rutgers University investigators say they've identified a protein that may be the culprit behind treatment-resistant prostate cancer. Item   

> ApoCell, which specializes in biomarker detection and analysis, has been named one of Houston's fastest-growing private companies. Item

> A new case report published in Case Reports in Oncology backs up the use of Galectin-3 as a marker of cancer and inflammation. Item

> The companion biomarker sector should jump to $319 million by 2018, a new report concludes. Item

> Genalyte is working with the Barbara Davis Center for Childhood Diabetes at the University of Colorado School of Medicine to advance a biomarker panel for early diagnosis of Type 1 diabetes. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.